Global Multiple Cancer Monoclonal Antibodies Market

Report ID : 1112 | Published : 2021-07-26 | Pages: 140 | Format:

Cancer monoclonal antibodies are specific antibodies with identical immune cells that are clones of a single parent cell directed to specific cellular targets. Thus, monoclonal antibodies are preciously customizable due to their unique nature and play a crucial role in treating target-specific cancerous cells. Therefore, monoclonal antibodies technology is proven to be more effective than other cancer therapies.

The increasing incidence of cancer disease among the population is driving the growth of the market. For instance, as per the World Health Organization, cancer is the second leading cause of death worldwide, accounting for around 9.6 million deaths in the year 2018. Multiple cancers, including lung cancer, colorectal cancer, prostate cancer, and liver cancer, are the most common types of cancer among men, while breast cancer, cervical cancer, colorectal cancer, and thyroid cancer are the most common among women. Additionally, increasing spending on research and development by multinational pharmaceutical companies is expected to create lucrative market growth. However, the high cost of treatment therapy and drug development may restrain the growth of the market.

The Global Multiple Cancer Monoclonal Antibodies market is segmented on the basis of product type, indication type, and region. Based on the service, the market is divided into Cetuximab, Nivolumab, Atezolizumab, Ramucirumab, Pembrolizumab, Pembrolizumab Companion Diagnostic, Ipilimumab, and Cancer Biosimilar Drugs (Bevacizumab, Trastuzumab, Nimotuzumab, etc.). On the basis of indication type, the market is divided into Lung Cancer, Bladder Cancer, Breast cancer, Endometrial cancer, Ovarian cancer, Oesophageal cancer, Prostate cancer, Multiple Myeloma, Lymphoma, Renal Cell Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.

The key players of this market include Abbvie, Amgen, Bayer HealthCare, Biogen Idec, Eli Lilly, Genmab, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Roche, and Seattle Genetics, among others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Multiple Cancer Monoclonal Antibodies Market Snapshot

Chapter 4. Global Multiple Cancer Monoclonal Antibodies Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Market Dynamics - Drivers

4.3. Challenges/Restraints

4.4. Market Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Epidemiology Analysis -2020

4.7. Lung Cancer

4.8. Bladder Cancer

4.9. Breast cancer

4.10. Endometrial cancer

4.11. Ovarian cancer

4.12. Oesophageal cancer

4.13. Prostate cancer

4.14. Multiple Myeloma

4.15. Lymphoma

4.16. Renal Cell Cancer

4.17. Competitive Landscape & Market Share Analysis

4.18. Key Investments and Funding’s in Oncology 2019

4.19. COVID 19 Impact on Pharmaceutical and Oncology R&D Industry

Chapter 5. Market Segmentation 1: Product Types Estimates & Trend Analysis

5.1. Product Types & Market Share, 2018 & 2028

5.2. Market Size (Value)& Forecasts and Trend Analyses, 2018 to 2028 for the following Product Types:

5.2.1. Cetuximab

5.2.2. Nivolumab

5.2.3. Atezolizumab

5.2.4. Ramucirumab

5.2.5. Pembrolizumab

5.2.6. Pembrolizumab Companion Diagnostic

5.2.7. Ipilimumab

5.2.8. Cancer Biosimilar Drugs (Bevacizumab, Trastuzumab, Nimotuzumab, etc.)

Chapter 6. Multiple Cancer Monoclonal Antibodies Market Segmentation 2: Indication Types Estimates & Trend Analysis

6.1. Indication Types Analysis & Market Share, 2018 & 2028

6.2. Market Size (Value) & Forecasts and Trend Analyses, 2018 to 2028 for the following Indication Types:

6.2.1. Lung Cancer

6.2.2. Bladder Cancer

6.2.3. Breast cancer

6.2.4. Endometrial cancer

6.2.5. Ovarian cancer

6.2.6. Oesophageal cancer

6.2.7. Prostate cancer

6.2.8. Multiple Myeloma

6.2.9. Lymphoma

6.2.10. Renal Cell Cancer

6.2.11. Others

Chapter 7. Multiple Cancer Monoclonal Antibodies Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2018-2028

7.1.2. North America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2018-2028

7.1.3. North America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by country, 2018-2028

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2018-2028

7.2.2. Europe Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2018-2028

7.2.3. Europe Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, 2018-2028

7.2.3.1. Germany

7.2.3.2. Poland

7.2.3.3. France

7.2.3.4. Italy

7.2.3.5. Spain

7.2.3.6. UK

7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2018-2028

7.3.2. Asia Pacific Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2018-2028

7.3.3. Asia Pacific Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, 2018-2028

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2018-2028

7.4.2. Latin America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2018-2028

7.4.3. Latin America Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, (US$ Million) 2018-2028

7.4.3.1. Brazil

7.4.3.2. Rest of Latin America

7.5. MEA

7.5.1. MEA Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Product Types, 2018-2028

7.5.2. MEA Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indication Types, 2018-2028

7.5.3. MEA revenue Multiple Cancer Monoclonal Antibodies Market revenue (US$ Million) by country, (US$ Million) 2018-2028

7.5.3.1. South Africa

7.5.3.2. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances in Biosimilar Industry

8.2. Company Profiles

8.2.1. Abbvie

8.2.2. Amgen

8.2.3. Bayer HealthCare

8.2.4. Biogen Idec

8.2.5. Eli Lilly

8.2.6. Genmab

8.2.7. Gilead Sciences

8.2.8. GlaxoSmithKline

8.2.9. Novartis

8.2.10. Pfizer

8.2.11. Roche

8.2.12. Seattle Genetics

8.3. List of Other Prominent Players

Global Multiple Cancer Monoclonal Antibodies Market Segmentation:

Global Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Product Type

  • Cetuximab
  • Nivolumab
  • Atezolizumab
  • Ramucirumab
  • Pembrolizumab
  • Pembrolizumab Companion Diagnostic
  • Ipilimumab
  • Cancer Biosimilar Drugs (Bevacizumab, Trastuzumab, Nimotuzumab, etc.)

Global Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) Based on Indication Type

  • Lung Cancer
  • Bladder Cancer
  • Breast cancer
  • Endometrial cancer
  • Ovarian cancer
  • Oesophageal cancer
  • Prostate cancer
  • Multiple Myeloma
  • Lymphoma
  • Renal Cell Cancer
  • Others

Global Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) Based on Region

Europe Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country

  • U.S.
  • Canada

Asia Pacific Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Multiple Cancer Monoclonal Antibodies Market Revenue (US$ Mn) by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients